Source: LevelJump Healthcare Corp.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Common shares of LevelJump (JUMP) are now eligible for electronic clearing and settlement through the DTC
  • DTC eligibility simplifies the process of trading and transferring the company’s common shares between brokerages in the United States
  • LevelJump’s common shares will continue to trade under the ticker symbol JMPHF on the OTCQB
  • LevelJump Healthcare is a national medical diagnostic imaging company providing radiology support to hospitals, emergency rooms and private clinics
  • LevelJump Healthcare Corp. (JUMP) is up 5.56 per cent, trading at C$0.19 per share at 1:30 pm ET

Common shares of LevelJump (JUMP) are now eligible for electronic clearing and settlement through the DTC. 

DTC is a subsidiary of the Depository Trust & Clearing Corp. (DTCC) that manages the electronic clearing and settlement of publicly-traded companies in the United States.

LevelJump’s common shares will continue to trade under the ticker symbol JMPHF on the OTCQB.

Through an electronic method of clearing securities, DTC eligibility simplifies the process of trading and transferring the company’s common shares between brokerages in the United States.

Mitch Geisler, CEO commented on the benefits of DTC eligibility.

“With DTC eligibility, our shares will be more accessible to a broader range of investors in the U.S. This should allow LevelJump to increase its global shareholder base and increase the liquidity of our common shares to the benefit of all investors.” 

LevelJump Healthcare is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers.

LevelJump Healthcare Corp. (JUMP) is up 5.56 per cent, trading at C$0.19 per share at 1:30 pm ET.

More From The Market Herald
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.

" NervGen Pharma (TSXV:NGEN) announces leadership changes

NervGen Pharma Corp. (NGEN) has announced several leadership changes.